4 recruiting, 2 active not recruiting. 6 Phase 3, 1 Phase 2.
By phase and status
Follow Odronextamab: new trials by email Literature Review of Odronextamab trials Research Report on Odronextamab
Trials (filtered) newest first · largest first
All 6 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Odronextamab, Loncastuximab tesirine, Rituximab - B-cell Non Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | 210 | 2024-05-02 | 2026-02-20 |
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
Odronextamab, Ifosfamide, Carboplatin - B-Cell Non-Hodgkin Lymphoma (B-NHL) | Phase 3 | Active not recruiting | 216 | 2024-02-15 | 2026-05-11 |
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Odronextamab, Lenalidomide, Rituximab - Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) | Phase 3 | Recruiting | 580 | 2023-12-28 | 2026-10-07 |
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Odronextamab, Rituximab, Cyclophosphamide - Diffuse Large B-cell Lymphoma (DLBCL) | Phase 3 | Recruiting | 904 | 2023-12-13 | 2026-10-07 |
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Odronextamab, Rituximab, Cyclophosphamide - Follicular Lymphoma (FL) | Phase 3 | Recruiting | 822 | 2023-12-12 | 2026-10-06 |
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
Odronextamab, Rituximab, Cyclophosphamide - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | 733 | 2023-11-14 | 2026-02-06 |
Conditions studied
Lymphoma, Follicular (3) · Lymphoma, B-Cell (2) · Recurrence (2) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1)
Sponsors
Regeneron Pharmaceuticals (5) · University of Birmingham (1)
Countries
Australia (6) · Austria (5) · Belgium (5) · Brazil (5) · Spain (5) · Taiwan (5) · Turkey (Türkiye) (5) · United Kingdom (5) · Chile (4) · Czechia (4) · France (4) · Germany (4) · Israel (4) · Italy (4) · Poland (4)
Top investigators
Amos Burke (1)